Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study of its experimental cancer drug APR-1051, an early signal the company …
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ATI-2138, showing rapid, near-complete, and sustained hair regrowth in a severe mouse model …
Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study Read More
NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) said it has completed enrollment in a 90-patient Phase 2 study testing its experimental oral COVID-19 treatment ratutrelvir against PAXLOVID®, reporting early …
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones Read More
PHILADELPHIA, PA — Aro Biotherapeutics said it will present interim clinical data next month from its ongoing Phase 1b trial of ABX1100, an experimental therapy aimed at treating late-onset Pompe …
Experimental Pompe Therapy Shows Early Signal Ahead of Key San Diego Reveal Read More
ONSHOHOCKEN, PA — Suvoda said it made significant strides in 2025 toward simplifying the clinical trial experience for patients and research sites, pointing to its merger with Greenphire, expanded product …
Suvoda Bets on Merger, AI to Simplify Clinical Trials and Boost Growth Read More
PHILADELPHIA, PA & SAN FRANCISCO, CA & SHANGHAI, China — Dispatch Bio and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) said they have entered into a clinical collaboration to conduct …
Dispatch Bio and CARsgen Strike China Deal to Test New CAR T Approach Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed meaningful reductions in disease progression for patients with geographic atrophy, a …
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said detailed clinical data from early-stage studies of its long-acting hormone-suppressing drug Teverelix have been accepted for presentation at a major international …
Medicus Gene-Blocking Drug Shows Fast Hormone Control Ahead of Key Endocrine Meet Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it has launched a placebo-controlled Phase 1b proof-of-concept trial of ATI-052, an experimental bispecific antibody aimed at treating atopic dermatitis, marking …
Aclaris Pushes New Antibody Into Skin Disease Trial, Eyes Asthma Next Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said newly published clinical trial data support the safety and early effectiveness of its experimental gene therapy for Stargardt disease, a rare inherited …
Gene Therapy Slows Vision Loss in Stargardt Trial, Fueling Hope for First Treatment Read More